NCT00624767View on ClinicalTrials.gov

A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

April 30, 2008

Study Completion Date

May 31, 2008

Conditions
Diabetes Mellitus
Interventions
DRUG

Insulin (recombinant human insulin)

Insulin Nasal Spray at doses up to 200 IU.

DRUG

NovoLog

NovoLog at doses up to 30 IU

Trial Locations (1)

78258

Diabetes and Glandular Disease Research Associates, San Antonio

Sponsors
All Listed Sponsors
lead

Nastech Pharmaceutical Company, Inc.

INDUSTRY